Valuation models
price $90.25 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused82.92 – 190.32119.8125% undervaluedDCF · Perpetuity growth · 10y99.65 – 213.79139.1635% undervaluedDCF · EBITDA exit · 5y181.03 – 202.51191.4753% undervaluedDCF · EBITDA exit · 10y183.52 – 225.23203.3556% undervaluedP/E · peers50.79 – 211.4870.6828% overvaluedP/E · own history74.09 – 106.7985.526% overvaluedPEG—201.2555% undervaluedEV/EBITDA · peers12.62 – 88.1940.24124% overvaluedEV/Revenue · peers34.35 – 133.5569.4430% overvaluedEarnings power value51.87 – 118.0677.1517% overvaluedDividend discount56.34 – 135.8084.637% overvaluedWall St. consensus target—112.0019% belowCost of capital (WACC)—6.35%—
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. How the headline model is chosen.
Model value · DCF · Perpetuity growth · 5y
119.81
CVS Health closed at $90.25 — undervalued by 25% vs model.
82.92the model's range190.32
DCF · Perpetuity growth · 5y leads for a mature, steady company — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
40.24 – 203.35
Wall St. target
112.00 19% below
Below model, 1y
6 of 31 days
How it is valued
Valued asMature & stable
Low/slowing growth (~6% recent)Thin margins (0.4% net margin)Pays dividendsHighly cyclical earningsStrong FCF yield (6.8%)
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.